share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股sec公告 ·  05/03 07:06
Moomoo AI 已提取核心訊息
On April 30, 2024, bluebird bio, Inc. amended its Loan and Security Agreement (LSA) with Hercules Capital, Inc. and other lenders. This amendment is in response to the company's delay in filing its Annual Report on Form 10-K for 2023 and its Quarterly Report for Q1 2024 due to the restatement of its financials for 2022 and the first three quarters of 2023. The amendment includes revised financial reporting metrics and extended deadlines for the company to provide its financial statements for the year ended December 31, 2023, and for the quarter ended March 31, 2024. The company has stated that the late filings will not be considered a violation of its legal compliance obligations, provided the documents are filed by the new deadlines. The announcement also contains forward-looking statements regarding the company's expectations for filing the delayed reports and its performance under the LSA.
On April 30, 2024, bluebird bio, Inc. amended its Loan and Security Agreement (LSA) with Hercules Capital, Inc. and other lenders. This amendment is in response to the company's delay in filing its Annual Report on Form 10-K for 2023 and its Quarterly Report for Q1 2024 due to the restatement of its financials for 2022 and the first three quarters of 2023. The amendment includes revised financial reporting metrics and extended deadlines for the company to provide its financial statements for the year ended December 31, 2023, and for the quarter ended March 31, 2024. The company has stated that the late filings will not be considered a violation of its legal compliance obligations, provided the documents are filed by the new deadlines. The announcement also contains forward-looking statements regarding the company's expectations for filing the delayed reports and its performance under the LSA.
2024年4月30日,藍鳥生物公司修訂了與赫拉克勒斯資本公司和其他貸款機構簽訂的貸款和擔保協議(LSA)。該修正案是對該公司因重報2022年和2023年前三個季度的財務狀況而推遲提交其2023年10-K表年度報告和2024年第一季度季度報告的回應。該修正案包括修訂後的財務報告指標,並延長了公司提供截至2023年12月31日的年度和截至2024年3月31日的季度財務報表的最後期限。該公司表示,延遲提交的文件不會被視爲違反其法律合規義務,前提是文件是在新的截止日期之前提交的。該公告還包含有關公司對提交延遲報告的預期及其在LSA下的業績的前瞻性陳述。
2024年4月30日,藍鳥生物公司修訂了與赫拉克勒斯資本公司和其他貸款機構簽訂的貸款和擔保協議(LSA)。該修正案是對該公司因重報2022年和2023年前三個季度的財務狀況而推遲提交其2023年10-K表年度報告和2024年第一季度季度報告的回應。該修正案包括修訂後的財務報告指標,並延長了公司提供截至2023年12月31日的年度和截至2024年3月31日的季度財務報表的最後期限。該公司表示,延遲提交的文件不會被視爲違反其法律合規義務,前提是文件是在新的截止日期之前提交的。該公告還包含有關公司對提交延遲報告的預期及其在LSA下的業績的前瞻性陳述。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息